25 Nov Asthma and COPD: Results of Clinical Trials of dual PDE3 and PDE4 inhibitor
MedicalResearch.com Interview with:
Professor Clive Page
Director, Sackler institute of Pulmonary Pharmacology
Joint Head, Institute of Pharmaceutical Science
King’s College London
150 Stamford Street Waterloo Campus
London SE1 9NH
MedicalResearch.com: What are the main findings of the study?
Prof. Page: RPL 554 was shown to cause bronchodilation and anti-inflammatory activity at the same dose. The drug showed benefit in both patients with COPD and asthma.
MedicalResearch.com: Were any of the findings unexpected?
Prof. Page: Our results were compatible with the activity of RPL 554 to act as an inhibitor of PDE3 (to elicit bronchodilation) and PDE4 (to elicit the anti-inflammatory activity).
MedicalResearch.com What should clinicians and patients take away from your report?
Prof. Page: That we have discovered a new class of bronchodilator that has concomitant anti-inflammatory activity which could provide extra clinical benefit to existing drugs used in the treatment of respiratory diseases such as asthma and COPD.
MedicalResearch.com: What recommendations do you have for future research as a result of this study?
Prof. Page: Further research in patients with more severe disease and to look at longer term studies to investigate whether the drug could provide an alternative to existing therapy for maintenance treatment